

Hereditary gastrointestinal polyposis syndromes Rare Disease Collaborative Network consensus statement agreed at the RDCN meeting Birmingham 17th February 2022

Clark, Susan; Cuthill, Vicky; Hawkins, Jackie; Hyer, Warren; Latchford, Andy; Sinha, Ashish; Din, Farhat; Beggs, Andrew; Desai, Anant; Morton, Dion; Hitchen, Debbie; Hill, James; Laloo, Fiona; Newton, Katy; Pugh, Sarah; Dolwani, Sunil; Hargest, Rachel; Horwood, James; Ramaraj, Raji; Rogers, Mark

DOI:

[10.1038/s44276-023-00011-z](https://doi.org/10.1038/s44276-023-00011-z)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Clark, S, Cuthill, V, Hawkins, J, Hyer, W, Latchford, A, Sinha, A, Din, F, Beggs, A, Desai, A, Morton, D, Hitchen, D, Hill, J, Laloo, F, Newton, K, Pugh, S, Dolwani, S, Hargest, R, Horwood, J, Ramaraj, R, Rogers, M, Collins, P, McNichol, F, Beck, N, Side, L & McDermott, FD 2023, 'Hereditary gastrointestinal polyposis syndromes Rare Disease Collaborative Network consensus statement agreed at the RDCN meeting Birmingham 17th February 2022', *BJC Reports*, vol. 1, no. 1, 10 . <https://doi.org/10.1038/s44276-023-00011-z>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 04. Oct. 2024

CORRESPONDENCE OPEN



Hereditary gastrointestinal polyposis syndromes Rare Disease Collaborative Network consensus statement agreed at the RDCN meeting Birmingham 17th February 2022

© The Author(s) 2023

BJC Reports; <https://doi.org/10.1038/s44276-023-00011-z>**INTRODUCTION**

NHS England set out in the *Implementation Plan for the UK Strategy for Rare Diseases* (<https://www.england.nhs.uk/wp-content/uploads/2018/01/implementation-plan-uk-strategy-for-rare-diseases.pdf>) that it would develop and implement Rare Disease Collaborative Networks (RDCNs), with the definition of a RDCN being a 'recognised network of member providers, each of which has demonstrable research-active interest in a rare/very rare disease, the aim of the network being to improve patient outcomes'. The network is composed of Rare Disease Collaborative Centres. A Rare Disease Collaborative Centre (RDCC) is a 'provider that has been recognised as having a demonstrable research-active interest in a rare/very rare disease and who works with other recognised providers in a network to improve patient outcomes'.

This initiative is also in line with the NHS England Board paper '12 Actions to Support and Apply Research in the NHS' discussed on 30 November 2017 (<https://www.england.nhs.uk/wp-content/uploads/2018/05/12-actions-to-support-and-apply-research-in-the-nhs.pdf>).

CONDITIONS COVERED

- Familial adenomatous polyposis.
- *MutYH*-associated polyposis.
- Polymerase proofreading associated polyposis.
- Peutz-Jeghers syndrome.
- Juvenile polyposis syndrome.
- Other ultra-rare Mendelian polyposis syndromes.

RARE DISEASE COLLABORATIVE CENTRES AND NETWORK

The following centres are now recognised by NHSE:

- Birmingham.
- Cardiff.
- Edinburgh.
- Manchester (with Liverpool).
- South West (Exeter/Plymouth).
- Southampton.
- St Mark's Hospital, London.

Each of these Centres has demonstrated compliance with commitment 24 of the UK Strategy for Rare Diseases

(https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/867940/dhsc-2020-update-to-the-rare-diseases-implementation-plan-for-england.pdf):

- Has a sufficient caseload to build recognised expertise.
- Service does not rely on a single clinician.
- Co-ordinates care.
- Arranges for co-ordinated transition from children's to adult services.
- Involves people with the rare disease, and their families and carers.
- Supports research activity.

PRINCIPLES OF CLINICAL CARE

Patients and families with an hereditary gastrointestinal polyposis syndrome need lifelong care and support, with personalised key clinical decisions including around:

- Type and timing of colorectal surgery to prevent bowel cancer.
- Intestinal endoscopic surveillance programmes according to disease severity and underlying genetic cause of disease.
- Requirement for extra-intestinal surveillance. Patients with these conditions require lifelong care.
- Cascade genetic testing and surveillance of family members.
- Family planning/pre-implantation genetic diagnosis.

CURRENT SITUATION

Currently the majority of patients and families with an hereditary gastrointestinal polyposis syndrome have care locally under non-specialists, often non-compliant with current guidelines, without sufficient experience and without offering access to research. Countless examples can be provided of suboptimal care when patients are managed outside of a structured, multidisciplinary polyposis service.

This continues despite the existence of centres of excellence, national and international guidelines, and published evidence demonstrating that outcomes are significantly improved by care in a specialist centre with dedicated call-up arrangements.

FUTURE PROVISION OF CARE

We believe that the current inequality in access to care and research is best addressed by development of the RDCN consisting of RDCC's providing high quality specialist care, with

consistent adherence to national evidence-based guidelines and standards, and collaborating in research.

Eventually all patients and families with an hereditary gastrointestinal polyposis syndrome should have their care delivered by one of these centres, with local pathways being developed to facilitate referral and patient data management systems/registries being put in place to allow effective recall, standardisation of data collection and monitoring of agreed KPI's.

Until sufficient resource has been established within the RDCN to accommodate all patients, it is acceptable that aspects of their care (eg genetic testing, risk reduction surgery, endoscopic surveillance) be provided outside of the network, provided that current guidelines are followed and these key aspects are discussed and documented at the MDT of one of RDCC's:

- Timing and type of risk reduction surgery.
- Endoscopic management of polyps.
- Management of extra-intestinal manifestations.

Susan Clark^{1,2✉}, Vicky Cuthill¹, Jackie Hawkins¹, Warren Hyer¹, Andy Latchford^{1,2}, Ashish Sinha^{1,2}, Farhat Din³, Andrew Beggs^{4,5}, Anant Desai⁵, Dion Morton^{4,5}, Debbie Hitchen⁶, James Hill⁶, Fiona Laloo⁷, Katy Newton⁶, Sarah Pugh⁷, Sunil Dolwani⁸, Rachel Hargest⁹, James Horwood⁹, Raji Ramaraj¹⁰, Mark Rogers¹¹, Paul Collins¹², Frances McNichol¹³, Nicholas Beck¹⁴, Lucy Side¹⁵ and Frank McDermott¹⁶

¹The St Mark's Centre for Familial Intestinal Cancer, St Mark's Hospital, London North West University Healthcare NHS Trust, London, UK. ²Department of Surgery and Cancer, Imperial College, London, UK. ³Institute of Genetics and Cancer, The University of Edinburgh, Western General Hospital Campus, Edinburgh, UK.

⁴Institute of Cancer and Genomic Sciences, College of Medical and Dental Science, University of Birmingham, Birmingham, UK.

⁵Department of Surgery, Queen Elizabeth Hospital, Birmingham, UK.

⁶Department of Colorectal Surgery, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. ⁷Clinical Genetics Service, Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. ⁸Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK. ⁹Department of Colorectal Surgery, University Hospital of Wales, Cardiff, UK. ¹⁰Department of Gastroenterology,

University Hospital Llandough, Cardiff, UK. ¹¹Department of Medical Genetics, Cardiff University, Cardiff, UK. ¹²Department of Gastroenterology and Hepatology, Royal Liverpool University Hospital, Liverpool, UK. ¹³Department of Colorectal Surgery, Royal Liverpool University Hospital, Liverpool, UK. ¹⁴Colorectal Unit, University Hospitals Southampton NHS Foundation Trust, Southampton, UK. ¹⁵Wessex Clinical Genetics Service, University Hospital Southampton NHS Foundation Trust, Southampton, UK. ¹⁶Royal Devon University HealthCare NHS Foundation Trust, Exeter, UK. ✉email: s.clark@nhs.net

AUTHOR CONTRIBUTIONS

All authors contributed to the manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Susan Clark.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023